ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2019, Vol. 11 ›› Issue (5): 415-418.doi: 10.3969/j.issn.1674-3865.2019.05.012

• 临床研究 • 上一篇    下一篇

补肺益气汤辅助治疗支气管哮喘患儿的疗效评价及对炎症因子水平的影响

李哲，杨红，徐荣燕，刘平，石岩，张义堂   

  1. 473000 河南 南阳，南阳市中心医院儿科
  • 出版日期:2019-11-01 发布日期:2019-11-08
  • 通讯作者: 杨红，E-mail：987116042@qq.com
  • 作者简介:李哲（1988-），男，医师。研究方向：儿童重症疾病的诊治

Efficacy of Bufei Yiqi decoction in adjuvant therapy for child patients with bronchial asthma and its influence on the levels of inflammatory factors

LI Zhe, YANG Hong, XU Rongyan, LIU Ping, SHI Yan, ZHANG Yitang   

  1. Department of Pediatrics, Nanyang Central Hospital, Nanyang 473000, China
  • Online:2019-11-01 Published:2019-11-08

PDF (PC)

105

摘要：
目的
探讨补肺益气汤辅助治疗支气管哮喘患儿的效果及对炎症因子水平的影响。
方法
选择2018年1月至12月南阳市中心医院收治的轻中度支气管哮喘患儿128例作为研究对象，随机分为观察组和对照组各64例。对照组给予布地奈德等止咳平喘、扩张支气管、抗感染对症支持治疗，观察组在对照组治疗基础上联合使用补肺益气汤加减治疗。比较两组患儿临床疗效，观察治疗前、治疗1周后两组患儿肺功能指标（总气道阻力、中心气道阻力、周围气道阻力）变化情况及血清炎症因子［C反应蛋白（CRP）、嗜酸性粒细胞（EOS）、白细胞介素-4（IL-4）、白细胞介素-10（IL-10）］水平。
结果
治疗1个月后观察组患儿临床总有效率为96.8%（62/64），显著高于对照组87.5%（54/64），差异有统计学意义(P<0.05）。治疗1个月后两组患儿肺功能指标中心气道阻力、总气道阻力水平显著低于治疗前，周围气道阻力高于治疗前，且观察组中心气道阻力、总气道阻力水平显著低于对照组，周围气道阻力水平显著高于对照组，差异均有统计学意义（P<0.05）。治疗1个月后两组患儿CRP、EOS、IL-4显著低于治疗前，IL-10显著高于治疗前，差异均有统计学意义（P<0.05）；观察组CRP、EOS、IL-4显著低于对照组，IL-10显著高于对照组，差异均有统计学意义（P<0.05）。
结论
补肺益气汤加减联合布地奈德治疗支气管哮喘患儿疗效显著，能有效改善患儿临床症状，提高肺功能。

关键词: 支气管哮喘, 补肺益气汤, 肺功能, 炎症因子, 儿童

Abstract:
Objective
To explore the effects of Bufei Yiqi decoction in adjuvant therapy for child patients with bronchial asthma and its influence on levels of inflammatory factors.
-Methods
Totally 128 child patients with mild-to-moderate bronchial asthma who were treated in Nanyang Central Hospital from -January- 2018 to December 2018 were selected as study subjects and were randomly divided into observation group(64 cases) and control group(64 cases). Both groups were given budesonide and other antitussive and antiasthmatic, bronchus-dilating and anti-infective symptomatic supportive treatment, and observation group was also given modified Bufei Yiqi decoction. The clinical efficacy in the two groups was compared. The changes in lung function indexes (total airway resistance, central airway resistance, peripheral airway resistance) and levels of serum inflammatory factors ［C-reactive protein(CRP), eosinophil(EOS), interleukin-4(IL-4), interleukin-10(IL-10)］ were observed in the two groups before treatment and after 1 week of treatment.
Results
After 1 month of treatment, the total clinical effective rate in observation group was significantly higher than that in control group［96.8%(62/64) vs.87.5%(54/64)］(P<0.05). After 1 month of treatment, the central airway resistance and total airway resistance in the the two groups were significantly lower than those before treatment, while the peripheral airway resistance was higher; the central airway resistance and total airway resistance in observation group were significantly lower than those in control group, while the peripheral airway resistance was significantly higher(P<0.05). After 1 month of treatment, the levels of CRP, EOS and IL-4 in the two groups were significantly lower than those before treatment, while the IL-10 level was significantly higher(P<0.05). The levels of CRP, EOS and IL-4 in observation group were significantly lower in observation group than those in control group, while the IL-10 level was significantly higher(P<0.05).
Conclusion
Modified Bufei Yiqi decoction combined with budesonide has significant efficacy in the treatment of child patients with bronchial asthma, and it can effectively improve the clinical symptoms and enhance the lung function of child patients.

Key words: Bronchial asthma, Bufei Yiqi decoction, Lung function, Inflammatory factors, Children